Please assess the completion status of the following clinical trial:

Trial Title: Echinaforce COVID-19 Shedding Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 12 - 75 years.~* Written informed consent.~* Ability and willingness to give oropharyngeal swab samples.~* Positive pre-screening SARS-CoV-2 RT-PCR virus test with an above threshold viral load as per qPCR (Cq ≤ 27).~Exclusion Criteria:~* ≥76 years~* \<12 years.~* Participation in another clinical study in the past 30 days or planned during study conduct.~* Severe COVID19~* Intake of antimicrobial, antiviral, immune suppressive substances.~* Surgical intervention in the 3 months prior enrolment~* Known diabetes mellitus.~* Known and medicated atopy or asthma.~* Cystic Fibrosis, bronchopulmonary dysfunction, COPD.~* Known immune system disorders and degenerative disorders (autoimmune disorders, AIDS, leukemia, lymphoma, myeloma).~* Known metabolic or resorption disorders.~* Known liver or kidney illnesses (chronic hepatitis, liver cirrhosis, chronic kidney insufficiency).~* Serious health conditions (limited general condition, auto-immune diseases, tumorous diseases, neurological disorders or serious Covid-19)~* Known allergies to plants of the compositae family (e.g. chamomile or dandelion) or to one of the compounds in the investigational product~* Known pregnancy.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- treatment group 1: Echinaforce Forte (EFF) Tablets (chewed) (Type: ACTIVE_COMPARATOR): 1st arm (EFF group): Slowly sucking 1 Echinaforce Forte tablet (1 tablet: 1'200mg EF) until dissolution Dose 1. Another 2 X 1 EF Forte tablets (total of 2 tablets: 2'400 mg EF) is taken one-by-one Dose 2 after swab sampling, which is repeated after complete dissolution of the second dose of EF Forte tablets.
- treatment gorup 2: Echinaforce Chewable (EFC) Tablets (chewed) (Type: ACTIVE_COMPARATOR): 2nd arm (EFC group): Slowly sucking 1 x 3 Echinaforce Chewable tablets (total 3 tablets: 1'200mg EF) until dissolution Dose 1. Another dose of 2 x 2 \& 1 x 3 EF Chewable tablets (total 7 tablets: 2'800mg EF) are slowly sucked Dose 2 after swab sampling, which is repeated after complete dissolution of the second dose of EF Chewable tablets.
- treatment group 3: Echinaforce Tincture (EFT, gargling) (Type: ACTIVE_COMPARATOR): 3rd arm (EFT group): Gargling of 2 x 19 drops of Echinaforce tincture (1'200 mg EF) is diluted in 2 x35 mL water Dose 1. Another dose of 3 x 30 drops of Echinaforce tincture (2'800 mg EF) diluted in 3 x35 mL water for 15 sec each Dose 2, gargled for 15 sec and swallowed after swab sampling, which is repeated after gargling of the second dose of EF Tincture.

Based on this trial design, predict the completion outcome and termination type (if applicable).